Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Rondo Therapeutics is a biopharmaceutical company dedicated to advancing cancer immunotherapies, particularly for solid tumors that are unresponsive to current treatments. Rondo's pipeline features multiple bispecific antibody programs, including RNDO-564 targeting CD28 and Nectin-4 for bladder cancer, and other programs in lead optimization and discovery stages for ovarian and undisclosed indications.

List your booth number for exhibitions, ask us